Founder and Chief Scientific Officer of CeeTox in Kalamazoo. Founded as a contract research organization, CeeTox provides support in the area of in vitro technology to help drug discovery scientists understand or predict the potentially adverse effects or toxicity of drugs before they get too far along in the development pipeline. McKim pulled together a team to form CeeTox as a Pfizer spinoff company. He has held many positions in 20 years as a toxicologist. At the University of Colorado School of Medicine he researched mechanisms underlying liver diseases in children. At Pharmacia (later Pfizer) he was director of the Global Center of Excellence for In Vitro Toxicology and developed and patented algorithms assessing in vivo toxicity risk. While at Dow, McKim received the company's Technical Achievement Award for research on the biological effects of silicone products. He has published numerous scientific manuscripts, book chapters, and reviews, and is a frequent speaker. North American Science Associates acquired CeeTox in 2008 and the company expanded its technology to the cosmetic and chemical industries. When Europe banned animal testing on makeup and personal care products, CeeTox developed expertise and research in the industry, gaining a number of European clients. PETA UK funded CeeTox to begin formal validation of a non-animal skin allergy test for regulatory use. In 2010, CeeTox acquired ADMETRx, another Pfizer spinoff. With financial support from the state, Southwest Michigan First, and the Michigan Small Business & Technology Development Center, CeeTox has been awarded contracts from the National Institute of Environmental Health Sciences, National Cancer Institute, National Institutes of Health Chemical Genomics Center, Food and Drug Administration, and the EPA. CeeTox was recently awarded a $26 million one-year contract with a potential maximum $130 million over five years as part of the EPA's program to develop cost-effective approaches for prioritizing and testing chemicals that need toxicity assessment. He is a diplomat of the American Board of Toxicology and has served as president of the Michigan Society of Toxicology. McKim graduated with honors from the doctoral program in biochemical and molecular toxicology at Oregon State University and trained as a postdoctoral fellow at the University of Kansas Medical School.